"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at aprepitant to treat a cough in people with lung cancer (CALC Trial)
This trial was done to find out if a drug called aprepitant can help people who have a cough as a symptom of lung cancer.
More about this trial
Cough is a common symptom of lung cancer. It can affect peoples’ quality of life. In this trial, researchers wanted to see if a drug called aprepitant (Emend) can help.
People in this trial had both aprepitant and a dummy drug (placebo) at different times. The research team compared how bad their cough was with the different treatments.
The aim of the trial was to find out if aprepitant relieves coughing more than a placebo in people with lung cancer.
Summary of results
The research team found that aprepitant did help people with lung cancer who had a cough.
This trial was open for people to join between 2013 and 2014. The research team presented the results at a conference in 2015.
About this trial/study
The research team recruited 20 people who had lung cancer and a cough. They were put in to one of two treatment groups at random.
Group 1 had aprepitant capsules for 3 days, then no treatment for 3 days, then dummy (placebo) capsules for 3 days.
Group 2 had placebo capsules for 3 days, then no treatment for 3 days, then aprepitant capsules for 3 days.
- 16 coughs per hour before treatment
- 13 coughs per hour on aprepitant
- 16 coughs per hour on the placebo
- 57 before treatment
- 41 on aprepitant
- 50 on the placebo
- 25 before treatment
- 20 on aprepitant
- 22 on placebo
How to join a clinical trial
Dr Fiona Blackhall
NIHR Clinical Research Network: Cancer
NIHR Fellowships Programme
NW Lung Charity
The Christie NHS Foundation Trust
University Hospital of South Manchester (UHSM)